Growth Metrics

Insight Molecular Diagnostics (IMDX) Operating Leases (2020 - 2023)

Historic Operating Leases for Insight Molecular Diagnostics (IMDX) over the last 4 years, with Q1 2023 value amounting to $2.6 million.

  • Insight Molecular Diagnostics' Operating Leases fell 2333.13% to $2.6 million in Q1 2023 from the same period last year, while for Mar 2023 it was $2.6 million, marking a year-over-year decrease of 2333.13%. This contributed to the annual value of $2.7 million for FY2022, which is 2301.83% down from last year.
  • Latest data reveals that Insight Molecular Diagnostics reported Operating Leases of $2.6 million as of Q1 2023, which was down 2333.13% from $2.7 million recorded in Q4 2022.
  • In the past 5 years, Insight Molecular Diagnostics' Operating Leases ranged from a high of $4.3 million in Q4 2020 and a low of $2.6 million during Q1 2023
  • Over the past 4 years, Insight Molecular Diagnostics' median Operating Leases value was $3.5 million (recorded in 2021), while the average stood at $3.4 million.
  • Per our database at Business Quant, Insight Molecular Diagnostics' Operating Leases tumbled by 1383.42% in 2022 and then crashed by 2333.13% in 2023.
  • Insight Molecular Diagnostics' Operating Leases (Quarter) stood at $4.3 million in 2020, then dropped by 17.79% to $3.5 million in 2021, then decreased by 23.02% to $2.7 million in 2022, then fell by 6.56% to $2.6 million in 2023.
  • Its Operating Leases was $2.6 million in Q1 2023, compared to $2.7 million in Q4 2022 and $2.9 million in Q3 2022.